|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Ruth M. Rothstein CORE Center |
|---|---|
| Information provided by: | Ruth M. Rothstein CORE Center |
| ClinicalTrials.gov Identifier: | NCT00227357 |
Purpose
The goal of this study is to develop and evaluate an innovative model of care to better serve patients who are both HIV-infected and opioid-dependent.
| Condition | Intervention |
|---|---|
|
HIV Infections AIDS Opiate Dependence Post-Traumatic Stress Disorders |
Drug: On-site - buprenorphine (Suboxone) Drug: Off-site - methadone or no agonist |
| Study Type: | Observational |
| Study Design: | Natural History, Longitudinal, Defined Population, Prospective Study |
| Official Title: | SPNS - An Evaluation of Innovative Methods for Integrating Buprenorphine Opioid Abuse Treatment in HIV Primary Care |
| Estimated Enrollment: | 120 |
| Study Start Date: | July 2005 |
| Estimated Study Completion Date: | December 2008 |
Hypothesis: HIV, opioid dependent patients provided agonist therapy at the site of their primary care will have better retention, utilization of services, health, social and quality of care measures and psychiatric treatment outcomes.
The Buprenorphine Project is an examination of two methods of service delivery. The purpose of this study is to assess the feasibility, cost and effectiveness of an intervention designed to integrate buprenorphine treatment for opioid dependence into HIV primary care at the CORE Center. For this project we will provide buprenorphine to 60 opioid dependent patients at any one time and will compare this on-site treatment group to 60 opioid dependent HIV+ patients who select off-site methadone or no agonist treatment at the time of enrollment.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| Contact: Mary Jo Tozzi, M.S. | (312) 572-4818 | mtozzi@corecenter.org |
| Contact: Jeffrey D. Watts, M.D. | (312) 572-4550 | jwatts@corecenter.org |
| United States, Illinois | |
| The CORE Center | Recruiting |
| Chicago, Illinois, United States, 60612 | |
| Contact: Mary Jo Tozzi, M.S. 312-572-4818 mtozzi@corecenter.org | |
| Contact: Jeffrey D. Watts, M.D. (312) 572-4550 jwatts@corecenter.org | |
| Principal Investigator: Jeffrey D. Watts, M.D. | |
| Principal Investigator: | Jeffrey D. Watts, M.D. | The CORE Center and John H. Stroger, Jr. Hospital of Cook County, Affiliates of the Cook County Bureau of Health Services |
More Information
| Study ID Numbers: | 1-H97HA03796-01-00 |
| Study First Received: | September 27, 2005 |
| Last Updated: | March 10, 2006 |
| ClinicalTrials.gov Identifier: | NCT00227357 History of Changes |
| Health Authority: | United States: Institutional Review Board |
|
HIV AIDS Buprenorphine Methadone |
Primary care dual diagnosis ptsd |
|
Respiratory System Agents Sexually Transmitted Diseases, Viral Slow Virus Diseases Narcotic Antagonists Physiological Effects of Drugs Disorders of Environmental Origin Opioid-Related Disorders Infection Stress Disorders, Traumatic Buprenorphine Mental Disorders Sensory System Agents Therapeutic Uses Substance-Related Disorders Stress Disorders, Post-Traumatic |
Analgesics Retroviridae Infections Analgesics, Opioid RNA Virus Infections Immune System Diseases Acquired Immunodeficiency Syndrome Central Nervous System Depressants Narcotics Pharmacologic Actions Immunologic Deficiency Syndromes Virus Diseases Methadone Anxiety Disorders HIV Infections Sexually Transmitted Diseases |